Growing evidence demonstrates that CP-AMPARs have a low probability of being detected in mature brains unless there are associated pathological events such as epilepsy (Malkin et al., 2016; Sun et al., 2018), ischemia (Noh et al., 2005; Kwak and Weiss, 2006), traumatic brain injury (Spaethling et al., 2008) and drug abuse (Ma et al., 2014, 2016, etc.). The gene discussed is CP; the disease is epilepsy.